An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver.
Ann Hepatol
; 12 Suppl 2: s3-35, 2013.
Article
em En
| MEDLINE
| ID: mdl-23559487
ABSTRACT
Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Oligopeptídeos
/
Inibidores de Proteases
/
Ribavirina
/
Prolina
/
Interferon-alfa
/
Hepatite C Crônica
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article